Twist Bioscience Corporation
TWSTNASDAQHealthcare● Active
$68.69
$-0.53(-0.77%)
Market Cap$4.3B
P/E Ratio—
52W High$72.99
52W Low$23.3
Twist Bioscience Corporation (TWST) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TWST · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.62
Est. -$0.49 · -26.5%
Revenue
$0.11B
Est. $0.11B · +2.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
TWST reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.48 | — | — | — | $0.11B | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$0.49 | -$0.62 | -26.5% | $0.11B | $0.11B | +2.9% |
| ▼ Q1 FY2026 | Feb 2, 2026 | -$0.48 | -$0.50 | -4.2% | $0.10B | $0.10B | +1.8% |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.50 | -$0.45 | +10.0% | $0.10B | $0.10B | +1.6% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$0.54 | -$0.47 | +13.0% | $0.10B | $0.10B | -1.4% |
| ▼ Q2 FY2025 | May 5, 2025 | -$0.56 | -$0.66 | -17.9% | $0.09B | $0.10B | -2.7% |
| ▲ Q1 FY2025 | Feb 3, 2025 | -$0.62 | -$0.53 | +14.5% | $0.09B | $0.09B | +2.0% |
| ▲ Q4 FY2024 | Nov 18, 2024 | -$0.71 | -$0.59 | +17.4% | $0.08B | $0.08B | +2.4% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.48
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$0.62
EPS Est.
-$0.49
EPS Surpr.
-26.5%
Revenue
$0.11B
Q1 FY2026
Feb 2, 2026Miss
EPS Actual
-$0.50
EPS Est.
-$0.48
EPS Surpr.
-4.2%
Revenue
$0.10B
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.50
EPS Surpr.
+10.0%
Revenue
$0.10B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
-$0.47
EPS Est.
-$0.54
EPS Surpr.
+13.0%
Revenue
$0.10B
Q2 FY2025
May 5, 2025Miss
EPS Actual
-$0.66
EPS Est.
-$0.56
EPS Surpr.
-17.9%
Revenue
$0.09B
Q1 FY2025
Feb 3, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.62
EPS Surpr.
+14.5%
Revenue
$0.09B
Q4 FY2024
Nov 18, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$0.71
EPS Surpr.
+17.4%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $-0.09 | $-0.09 | $-0.09 | 2 |
| Q2 FY2028 | $-0.14 | $-0.14 | $-0.14 | 2 |
| Q1 FY2028 | $-0.19 | $-0.19 | $-0.19 | 3 |
| Q4 FY2027 | $-0.21 | $-0.21 | $-0.21 | 2 |
| Q3 FY2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q2 FY2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -26.5% | $60.40 | $56.19 | -6.97% |
| ▼ Q1 FY2026 | Feb 2, 2026 | -4.2% | $41.07 | $46.81 | +13.98% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +10.0% | $29.90 | $26.87 | -10.13% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +13.0% | $33.68 | $30.21 | -10.30% |
| ▼ Q2 FY2025 | May 5, 2025 | -17.9% | $39.24 | $35.93 | -8.44% |
| ▲ Q1 FY2025 | Feb 3, 2025 | +14.5% | $52.37 | $52.75 | +0.73% |
| ▲ Q4 FY2024 | Nov 18, 2024 | +17.4% | $36.89 | $41.43 | +12.31% |
| ▼ Q3 FY2024 | Aug 2, 2024 | -8.9% | $53.05 | $42.97 | -19.00% |
Q2 FY2026-6.97%
Report Date
May 4, 2026
EPS Beat/Miss
-26.5%
Price Before
$60.40
Price After
$56.19
Q1 FY2026+13.98%
Report Date
Feb 2, 2026
EPS Beat/Miss
-4.2%
Price Before
$41.07
Price After
$46.81
Q4 FY2025-10.13%
Report Date
Nov 14, 2025
EPS Beat/Miss
+10.0%
Price Before
$29.90
Price After
$26.87
Q3 FY2025-10.30%
Report Date
Aug 4, 2025
EPS Beat/Miss
+13.0%
Price Before
$33.68
Price After
$30.21
Q2 FY2025-8.44%
Report Date
May 5, 2025
EPS Beat/Miss
-17.9%
Price Before
$39.24
Price After
$35.93
Q1 FY2025+0.73%
Report Date
Feb 3, 2025
EPS Beat/Miss
+14.5%
Price Before
$52.37
Price After
$52.75
Q4 FY2024+12.31%
Report Date
Nov 18, 2024
EPS Beat/Miss
+17.4%
Price Before
$36.89
Price After
$41.43
Q3 FY2024-19.00%
Report Date
Aug 2, 2024
EPS Beat/Miss
-8.9%
Price Before
$53.05
Price After
$42.97
Avg Beat Reaction-1.85%
Avg Miss Reaction-5.11%
Beat Rate4 / 8 quarters
Largest Move-19.00% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TWST ends December
Twist Bioscience Corporation (TWST) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.62 — missing the analyst consensus of $-0.49 by -26.5%. The next TWST earnings date is expected around September 1, 2026.
Each quarter, investors track TWST earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TWST revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TWST's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TWST earnings · 5 questionsTwist Bioscience Corporation's next earnings report is expected around September 1, 2026. TWST typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TWST historically reports after market close (AMC).
TWST earnings datewhen is TWST earningsTWST next earnings datewhen does TWST report earningsTWST earnings calendar
▸ Source: FMP · Twist Bioscience Corporation SEC filings · US GAAP · Twist Bioscience Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026